Principal Infrastructure Architect
Stanford University School of Medicine, Research IT
Dr. Martin is a clinical informatics specialist at Stanford. He has a PhD degree in Biochemistry from the Peter G. Schultz’s Laboratory at UC – Berkeley and a BA from Carleton College. His professional background is in informatics research and analysis in scientific domains, primarily biotech and small pharmaceutical R&D. He is a co-founder Scientist.com (formerly Assay Depot) – the world’s largest online marketplace for pharmaceutical services. Previously, he was Head of Informatics at Kalypsys, a high-throughput drug discovery and technology company. Andy has been consulting and working at Stanford for over six years. He currently serves on the board for the Firetree Asia Foundation and Scientist.com.
White Star Consulting
Jim Langford has been a leader in the pharmaceutical clinical development industry for over 25 years, where he has founded and managed several companies to leadership positions in the industry. He was the Founder and President of the PHOENIX, a Contract Research Organization (CRO) that provided clinical research services to the biopharmaceutical industry, until it was sold in 2002 to an international CRO based in Canada. While managing the PHOENIX, Jim founded an electronic data capture (EDC) company, DataLabs, which was spun out as an independent company in 2001. DataLabs was one of the leading EDC companies at the time of its acquisition by ClinPhone, Plc. in 2006. ClinPhone, Plc was subsequently acquired by PAREXEL International, who continues to use DataLabs in many of their clinical trials. Currently, Jim has been leading his consulting company, White Star Consulting, in providing executive management services within life science companies to assist them in improving their clinical development process with the use of technology in clinical operations, and outsourcing strategies. The companies include both public and private companies in the biopharmaceutical, medical device, technology, and most recently, in the emerging cell and gene therapy industries.